Nature's Sunshine Products Inc

Nature's Sunshine Products Inc(NATR)股票分析

$13.870

-0.275 (-1.98%)收盘时

Loading chart…
High
14.320
Open
14.160
VWAP
14.01
Vol
207.47K
Mkt Cap
281.51M
Low
13.840
Amount
2.91M
EV/EBITDA, TTM
7.91

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.

AI analysis of Nature's Sunshine Products Inc (NATR)

hold

Nature's Sunshine Products Inc (NATR) is currently not a strong buy due to recent performance declines and earnings misses. The stock is trading at $14.21, down 32.24% year-to-date, and the RSI is at a low 29.336, indicating potential oversold conditions. However, the forward P/E ratio is a reasonable 12.6422, suggesting some value, but the recent downgrade in revenue guidance and insider selling (161.97% increase in selling activity) presents significant risks.

估值指标

The current forward P/E ratio for Nature's Sunshine Products Inc (NATR) is 12.35, compared to its 5-year average forward P/E of 12.86.

Forward P/E

Fair
5Y Average P/E
12.86
Current P/E
12.35
高估
58.37
低估
-32.66

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
6.43
Current EV/EBITDA
7.91
高估
9.10
低估
3.76

Forward P/S

Undervalued
5Y Average P/S
0.63
Current P/S
0.48
高估
0.77
低估
0.49

Alphio AI Price Scenarios for NATR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NATR

$16.58

情景价格

B

Base

Base · 50%NATR

$16.06

情景价格

B

Bear

Bear · 25%NATR

$14.23

情景价格

Whales holding NATR

S

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

+ HoldingNATR

-21.30%

3M Return

事件时间线

2026-08-06 (ET)

18:30:00

Nature's Sunshine Appoints Ruth Perkins as CFO

2026-05-07 (ET)

17:50:00

Company Reports Q1 Revenue of $122.9M

17:50:00

Reiterates FY26 Revenue View of $500M-$515M

2026-04-30 (ET)

09:20:00

Nature's Sunshine Appoints John Hnanicek as CTO

2026-03-10 (ET)

16:30:00

Company Expects FY26 Adjusted EBITDA of $50M-$54M

资讯

NATR FAQ — answered by Alphio AI

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk. It operates in the Consumer Non-Cyclicals sector (PHARMACEUTICAL PREPARATIONS industry).

Nature's Sunshine Products Inc (NATR) is currently not a strong buy due to recent performance declines and earnings misses. The stock is trading at $14.21, down 32.24% year-to-date, and the RSI is at a low 29.336, indicating potential oversold conditions. However, the forward P/E ratio is a reasonable 12.6422, suggesting some value, but the recent downgrade in revenue guidance and insider selling (161.97% increase in selling activity) presents significant risks.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始